458 related articles for article (PubMed ID: 12149301)
41. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer.
Oettle H; Riess H
Cancer; 2002 Aug; 95(4 Suppl):912-22. PubMed ID: 12209671
[TBL] [Abstract][Full Text] [Related]
42. A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
Okusaka T; Ishii H; Funakoshi A; Ueno H; Furuse J; Sumii T
Jpn J Clin Oncol; 2006 Sep; 36(9):557-63. PubMed ID: 16870696
[TBL] [Abstract][Full Text] [Related]
43. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Yoo C; Hwang JY; Kim JE; Kim TW; Lee JS; Park DH; Lee SS; Seo DW; Lee SK; Kim MH; Han DJ; Kim SC; Lee JL
Br J Cancer; 2009 Nov; 101(10):1658-63. PubMed ID: 19826418
[TBL] [Abstract][Full Text] [Related]
44. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
[TBL] [Abstract][Full Text] [Related]
45. Unresectable pancreatic cancer: arterial embolization to achieve a single blood supply for intraarterial infusion of 5-fluorouracil and full-dose IV gemcitabine.
Tanaka T; Sho M; Nishiofuku H; Sakaguchi H; Inaba Y; Nakajima Y; Kichikawa K
AJR Am J Roentgenol; 2012 Jun; 198(6):1445-52. PubMed ID: 22623561
[TBL] [Abstract][Full Text] [Related]
46. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
Kindler HL; Niedzwiecki D; Hollis D; Sutherland S; Schrag D; Hurwitz H; Innocenti F; Mulcahy MF; O'Reilly E; Wozniak TF; Picus J; Bhargava P; Mayer RJ; Schilsky RL; Goldberg RM
J Clin Oncol; 2010 Aug; 28(22):3617-22. PubMed ID: 20606091
[TBL] [Abstract][Full Text] [Related]
47. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
[TBL] [Abstract][Full Text] [Related]
48. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
Colucci G; Labianca R; Di Costanzo F; Gebbia V; Cartenì G; Massidda B; Dapretto E; Manzione L; Piazza E; Sannicolò M; Ciaparrone M; Cavanna L; Giuliani F; Maiello E; Testa A; Pederzoli P; Falconi M; Gallo C; Di Maio M; Perrone F; ; ;
J Clin Oncol; 2010 Apr; 28(10):1645-51. PubMed ID: 20194854
[TBL] [Abstract][Full Text] [Related]
49. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris HA; Moore MJ; Andersen J; Green MR; Rothenberg ML; Modiano MR; Cripps MC; Portenoy RK; Storniolo AM; Tarassoff P; Nelson R; Dorr FA; Stephens CD; Von Hoff DD
J Clin Oncol; 1997 Jun; 15(6):2403-13. PubMed ID: 9196156
[TBL] [Abstract][Full Text] [Related]
50. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V
Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598
[TBL] [Abstract][Full Text] [Related]
51. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
Herrmann R; Bodoky G; Ruhstaller T; Glimelius B; Bajetta E; Schüller J; Saletti P; Bauer J; Figer A; Pestalozzi B; Köhne CH; Mingrone W; Stemmer SM; Tàmas K; Kornek GV; Koeberle D; Cina S; Bernhard J; Dietrich D; Scheithauer W; ;
J Clin Oncol; 2007 Jun; 25(16):2212-7. PubMed ID: 17538165
[TBL] [Abstract][Full Text] [Related]
52. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
53. Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.
Sultana A; Ghaneh P; Cunningham D; Starling N; Neoptolemos JP; Smith CT
BMC Cancer; 2008 Jul; 8():192. PubMed ID: 18611273
[TBL] [Abstract][Full Text] [Related]
54. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
[TBL] [Abstract][Full Text] [Related]
55. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
Landry J; Catalano PJ; Staley C; Harris W; Hoffman J; Talamonti M; Xu N; Cooper H; Benson AB
J Surg Oncol; 2010 Jun; 101(7):587-92. PubMed ID: 20461765
[TBL] [Abstract][Full Text] [Related]
56. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.
Maisey N; Chau I; Cunningham D; Norman A; Seymour M; Hickish T; Iveson T; O'Brien M; Tebbutt N; Harrington A; Hill M
J Clin Oncol; 2002 Jul; 20(14):3130-6. PubMed ID: 12118027
[TBL] [Abstract][Full Text] [Related]
57. A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).
Santasusana JM; García López JL; García JJ; Carbonero AI; Plazas JG; Rovira PS; Martos CF; Guzmán MC; Jericó JF; Delgado FJ; Espinosa JC; Muñoz ML; Aguilar EA; Valera JS; García Ribas I; Mena AC
Clin Transl Oncol; 2005 Dec; 7(11):493-8. PubMed ID: 16373060
[TBL] [Abstract][Full Text] [Related]
58. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
59. Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas.
Oztop I; Yilmaz U; Yavuzsen T; Yaren A; Tarhan O; Sagol O; Coker A; Alakavuklar M
Chemotherapy; 2004 Jun; 50(3):127-32. PubMed ID: 15282439
[TBL] [Abstract][Full Text] [Related]
60. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
